Patients with hyperuricemia
Conditions
Interventions
febuxostat adoministration group The patients with hyperuricemia (uric acid equal and more than 7 mg/dl) are treated with 10 mg/day of febuxostat for 14 days.
febuxostat non-adoministartion group
Sponsors
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) uric acid equal and more than 7 mg/dl 2) hospitalized patients 3) older than 19 years-old 4) without taking drugs lowered uric acid within 1 month before the informed consent acquisition
Exclusion criteria
Exclusion criteria: 1) Patients who have liver injury. 2) renal replacement therapy 3) Patients who are having gouty arthritis (gout attack) 4) History of ischemic heart disease or cerebrovascular disease within 3 month before the informed consent acquisition 5) Pateients who had severe side effects or allergic recation to febuxostat 6) Patients who are taking mercaptopurine, azathioprine, vidarabine and didanosine 7) Patients who are judged as inadequate to participate in the study by their doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| flow mediated vasodilation: FMD | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Pulse wave velocity: PWV 2) Serum uric acid, Urinary uric acid excretion, Uric acid clearance 3) 8-oxodG, 8-epi-PGF2alpha, MDA, oxLDL 4) nitric oxide metabolite 5) serum XOR activity 6) FABP4 7) hsCRP, s-VCAM1 8) side effects | — |
Countries
Japan
Contacts
Public ContactToshio Ohtsubo
Graduate school of Kyushu university Department of medicine and clinical science
Outcome results
None listed